Loading...
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose level...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Just Medical Media Limited
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4079288/ https://ncbi.nlm.nih.gov/pubmed/24991224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212262 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|